Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024316 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP
A Phase 1 study of Congenital Erythropoietic Porphyria (CEP), sponsored by Atlas Molecular Pharma.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
- 1
- Study location
NCT07024316 is a Phase 1 study of Congenital Erythropoietic Porphyria (CEP) that is actively recruiting participants, run by Atlas Molecular Pharma. The registered enrollment target is 6 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07024316, a Phase 1 study of Congenital Erythropoietic Porphyria (CEP), is actively recruiting participants, sponsored by Atlas Molecular Pharma.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
Conditions Studied
Interventions
- DRUG ATL-001 (Ciclopirox oral solution)
Study Locations (1)
Ohio
- The Cleveland Clinics - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2026-01-15 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07024316
The ClinicalTrials.gov registry entry for NCT07024316 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atlas Molecular Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Erythropoietic Porphyria (CEP) appearing as the primary indexed condition, and to 1 intervention - of which ATL-001 (Ciclopirox oral solution) is the first listed.
NCT07024316 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07024316 about?
NCT07024316 is a clinical study titled "A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP". This is a study to investigate the effect of oral ATL-001 (ciclopirox) in CEP (Congenital Erythropoietic Porphyria) patients. During the study, it will be measured the improvement of skin lesions, fatigue and other clinical symptoms as well as blood parameters. Funding source - FDA OOPD
What is the current status of trial NCT07024316?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2026-01-15. Estimated completion is 2027-11-01.
What conditions does trial NCT07024316 study?
This clinical trial studies the following conditions: Congenital Erythropoietic Porphyria (CEP).
What interventions are being tested in trial NCT07024316?
The interventions under investigation include: ATL-001 (Ciclopirox oral solution) (DRUG).
Who is sponsoring clinical trial NCT07024316?
This trial is sponsored by Atlas Molecular Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024316 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.